Rheumatoid Arthritis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Rheumatoid Arthritis stocks.

Rheumatoid Arthritis Stocks Recent News

Date Stock Title
Oct 2 IXHL Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL)
Oct 1 CVM CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
Sep 30 IXHL Incannex Healthcare GAAP EPS of -$1.15
Sep 30 IXHL Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
Sep 30 REGN Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sep 29 REGN Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
Sep 29 REGN Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales
Sep 29 REGN Regeneron: Long-Term Defensive Investment
Sep 28 PCRX Executive reshuffles: NSC, PCRX and OMI Companies in focus
Sep 28 CHRS Coherus BioSciences, Inc. (CHRS): Worst 52-Week Low Stock to Buy Now
Sep 28 REGN Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
Sep 28 REGN Wall Street Breakfast: What Moved Markets
Sep 28 REGN Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’
Sep 27 REGN Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Sep 27 REGN Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling
Sep 27 REGN FDA greenlights Regeneron’s Dupixent for the treatment of COPD
Sep 27 PCRX Pacira BioSciences appoints Lauren Riker as interim CFO
Sep 27 REGN Regeneron/ Sanofi granted FDA label expansion for Dupixent in COPD
Sep 27 REGN Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
Sep 27 REGN Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints. It typically results in warm, swollen, and painful joints. Pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also affect other parts of the body. This may result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Fever and low energy may also be present. Often, symptoms come on gradually over weeks to months.While the cause of rheumatoid arthritis is not clear, it is believed to involve a combination of genetic and environmental factors. The underlying mechanism involves the body's immune system attacking the joints. This results in inflammation and thickening of the joint capsule. It also affects the underlying bone and cartilage. The diagnosis is made mostly on the basis of a person's signs and symptoms. X-rays and laboratory testing may support a diagnosis or exclude other diseases with similar symptoms. Other diseases that may present similarly include systemic lupus erythematosus, psoriatic arthritis, and fibromyalgia among others.The goals of treatment are to reduce pain, decrease inflammation, and improve a person's overall functioning. This may be helped by balancing rest and exercise, the use of splints and braces, or the use of assistive devices. Pain medications, steroids, and NSAIDs are frequently used to help with symptoms. Disease-modifying antirheumatic drugs (DMARDs), such as hydroxychloroquine and methotrexate, may be used to try to slow the progression of disease. Biological DMARDs may be used when disease does not respond to other treatments. However, they may have a greater rate of adverse effects. Surgery to repair, replace, or fuse joints may help in certain situations. Most alternative medicine treatments are not supported by evidence.RA affects about 24.5 million people as of 2015. This is between 0.5 and 1% of adults in the developed world with 5 and 50 per 100,000 people newly developing the condition each year. Onset is most frequent during middle age and women are affected 2.5 times as frequently as men. In 2013, it resulted in 38,000 deaths up from 28,000 deaths in 1990. The first recognized description of RA was made in 1800 by Dr. Augustin Jacob Landré-Beauvais (1772–1840) of Paris. The term rheumatoid arthritis is based on the Greek for watery and inflamed joints.

Browse All Tags